Literature DB >> 2265242

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

H J Kolb1, J Mittermüller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim, W Wilmanns.   

Abstract

Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon alpha and transfusion of viable donor buffy coat. All had complete hematologic and cytogenetic remission, which persisted 32 to 91 weeks after treatment. In two patients graft-versus-host disease developed and was treated by immunosuppression. These results are an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2265242

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  213 in total

1.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Authors:  Marleen M van Loenen; Renate de Boer; Avital L Amir; Renate S Hagedoorn; Gerdien L Volbeda; Roelof Willemze; Johannes J van Rood; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

3.  Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.

Authors:  Yi-Fen Lu; L Cristina Gavrilescu; Monica Betancur; Katherine Lazarides; Hans Klingemann; Richard A Van Etten
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 4.  Suicide-gene-Transduced donor T-cells for controlled graft-versus-host disease and graft-versus-tumor.

Authors:  Fabio Ciceri; Claudio Bordignon
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 5.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.

Authors:  Valentina Nardi; Olaia Naveiras; Mohammad Azam; George Q Daley
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

7.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.

Authors:  Y Zeng; J Stokes; S Hahn; E Hoffman; E Katsanis
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

8.  Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone.

Authors:  Jeffrey S Miller; Daniel J Weisdorf; Linda J Burns; Arne Slungaard; John E Wagner; Michael R Verneris; Sarah Cooley; Rosanna Wangen; Susan K Fautsch; Roby Nicklow; Todd Defor; Bruce R Blazar
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

Review 9.  Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.

Authors:  Katherine A Baugh; Ifigeneia Tzannou; Ann M Leen
Journal:  Curr Opin Infect Dis       Date:  2018-08       Impact factor: 4.915

Review 10.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.